Adverse events following botulinum toxin type A treatment in children with cerebral palsy.
Langdon
Katherine
K
Blair
Eve
E
Davidson
Sue-Anne
SA
Valentine
Jane
J
D000293:Adolescent; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects*; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005242:Fecal Incontinence; D005260:Female; D006801:Humans; D008297:Male; D018908:Muscle Weakness / Q000139:chemically induced / Q000209:etiology*; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D011597:Psychomotor Performance / Q000145:classification; D014549:Urinary Incontinence; D014904:Western Australia; D055815:Young Adult
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A